

Regd. Office :  
1506, Chiranjiv Tower,  
43, Nehru Place, New Delhi-110019  
CIN No. : L74899DL1993PLC056594

Tel. : 011 - 47589500, 41608929  
Tel. : 011 - 21800032  
Fax : 011 - 26213081  
Web : www.medicamen.com

**Ref: STEX/OUTCOME/2019-20**

**Date: 14.08.2019**

**BSE Limited**  
Department of Corporate Services-Listing  
PJ Towers, Dalal Street  
Mumbai- 400001

**Company No.: 531146**

**Sub. : Outcome of Board Meeting.**

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results of the Company for the quarter ended on June 30, 2019.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Un-Audited Financial Results of the Company for the quarter ended on June 30, 2019 as **Annexure-A** and
- Limited Review Report on the Un- Audited Financial Results as **Annexure-B**

Further Board of Directors at their meeting approved the following resolutions:

- Approved draft Annual Report for the financial year 2018-19.
- Appointment of M/s SPB & Co, Cost Accountants as Cost Auditor of the Company for the financial year 2019-20.
- Appointment of M/s Cheena & Associates, Cost Accountants as Internal Auditor of the Company for the financial year 2019-20.
- Appointment of M/s AMJ & Associates, Company Secretaries as Secretarial Auditor of the Company for the financial year 2019-20.
- Considered and approved the Incorporation of a Subsidiary in Australia, in the name and style of 'Medicamen Biotech Australia Pty Ltd' to explore investments and to acquire any running Pharma opportunity in Australia.

The meeting of the Board of Directors commenced on 12.30 PM and concluded at 02.40 PM.

The Un-Audited Financial Results of the Company for the quarter ended on June 30, 2019, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,

**For Medicamen Biotech Limited**

  
  
**Rahul Bishnoi**  
**Chairman**  
**DIN: 00317960**

# MEDICAMEN BIOTECH LIMITED

Annexure - A

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

## Un-audited Standalone Financial Results for the quarter ended on 30th June' 2019

### PART I

Rupees in Lacs (Except per Share data)

Particulars	Quarter Ended			Year Ended
	3 Months Ended 30.06.2019	Preceding 3 Months Ended 31.03.2019	Corresponding 3 Months Ended 30.06.2018	31.03.2019
	Unaudited	Audited	Unaudited	Audited
<b>1 Income from operations</b>				
(a) Net Sales / Income from operations	3,112.91	3,327.04	3,276.34	12,260.45
(b) Other Income	3.84	61.92	116.29	365.87
(c) Total Revenue	<b>3,116.75</b>	<b>3,388.96</b>	<b>3,392.63</b>	<b>12,626.32</b>
<b>2 Expenses</b>				
a) Cost of Material Consumed	2,154.07	2,383.86	1,934.20	7,996.44
b) Purchase of Goods Traded	-	198.76	-	198.76
c) Changes in inventory of Finished Goods and Work in Progress	(69.75)	(45.96)	262.45	139.08
d) Employees Benefits Expenses	198.16	141.83	216.79	808.55
e) Finance Cost	16.39	2.56	35.77	93.77
f) Depreciation and Amortisation Expenses	56.96	66.04	47.70	221.40
g) Other expenses	329.15	220.14	441.73	1,397.12
<b>Total Expenses</b>	<b>2,684.98</b>	<b>2,967.24</b>	<b>2,938.64</b>	<b>10,855.13</b>
<b>3 Profit/(Loss) before Exceptional Items &amp; Tax ( 1 - 2 )</b>	<b>431.77</b>	<b>421.72</b>	<b>453.99</b>	<b>1,771.19</b>
<b>4 Exceptional Items (Commercial Tax Expenses Related to Earlier Years)</b>	-	-	-	-
<b>5 Profit/(Loss) before Extra Ordinary Items &amp; Tax (3 - 4 )</b>	<b>431.77</b>	<b>421.72</b>	<b>453.99</b>	<b>1,771.19</b>
<b>6 Tax Expenses</b>				
Current Year	111.00	123.39	133.71	549.63
MAT Credit Entitlement	-	-	-	-
Deferred Tax Liability	(7.36)	14.39	(1.92)	0.07
<b>Total Tax Expense</b>	<b>103.64</b>	<b>137.78</b>	<b>131.79</b>	<b>549.70</b>
<b>7 Net Profit /Loss for the period from Continuing operation (5- 6)</b>	<b>328.13</b>	<b>283.94</b>	<b>322.20</b>	<b>1,221.49</b>
<b>8 Other Comprehensive Income</b>				
Item that will not reclassified to Profit & Loss	-	-	-	-
<b>9 Total Comprehensive Income net of Tax</b>	<b>328.13</b>	<b>283.94</b>	<b>322.20</b>	<b>1,221.49</b>
<b>10 Paid up equity share capital (Rs. 10/- per share)</b>	<b>1,221.66</b>	<b>1,170.00</b>	<b>1,170.00</b>	<b>1,170.00</b>
<b>11 Earning Per Share (Rs.)</b>				
Basic	2.75	2.43	2.75	10.44
Diluted	2.75	2.43	2.75	10.44

### NOTES :

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 14th August'2019.
- The figures are regrouped in previous year also, wherever considered necessary.
- The company operates only in one business segment , viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Paid-up Share capital of the company has been increased from 11,70,00,000/- to Rs. 12,21,66,000/- pursuant to allotment of 5,16,600 number of equity shares @ 10/- each on dated 21.05.2019.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 -"Earning per Share"
- Limited review Report has been carried out by the Statutory Auditors for the above period.

For & on behalf of Board of Directors  
Medicamen Biotech Limited



*R. Bishnoi*

(Rahul Bishnoi)  
Chairman

Place : New Delhi

Dated : 14th August'2019



**RAI QIMAT & ASSOCIATES**  
CHARTERED ACCOUNTANTS**Independent Auditor's Review Report on Standalone Quarterly Financial Results**

To

The Board of Directors,  
**Medicamen Biotech Ltd.**  
1506, Chiranjiv Tower, 43,  
Nehru Place New Delhi-110019


We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter ended June 30, 2019 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Rai Qimat & Associates**  
**Chartered Accountants**

  
**Rai Qimat Rai Garg**  
**Partner**  
(Membership Number: 080857)  
UDIN : 19080857AAAABY4857

**Place: Gurugram**  
**Date: 14.08.2019**